Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Murielle Gantzer
Observed names:
Gantzer, Murielle,
M Gantzer
Institution:
Transgene (France)
Observed institution:
Transgene (France)
OpenAlex ID:
A5046488964
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
1996
·
C Chartier
, E Degryse
, et al.
·
Journal of Virology
·
707
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
2017
·
Laetitia Fend
, Takahiro Yamazaki
, et al.
·
Cancer Research
·
145
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
2016
·
Patricia Kleinpeter
, Laetitia Fend
, et al.
·
OncoImmunology
·
108
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
2017
·
Caroline Tosch
, Bérangère Bastien
, et al.
·
Journal for ImmunoTherapy of Cancer
·
80
PDF
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
2017
·
Christelle Remy-Ziller
, Christine Thioudellet
, et al.
·
Human Vaccines & Immunotherapeutics
·
36
PDF
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
2019
·
Patricia Kleinpeter
, Christelle Remy-Ziller
, et al.
·
Journal of Virology
·
26
Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2014
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
·
Cancer Immunology Research
·
22
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
2021
·
Jérémy Béguin
, Murielle Gantzer
, et al.
·
Scientific Reports
·
15
PDF
Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity
2005
·
Bruce Acres
, Murielle Gantzer
, et al.
·
Cancer Research
·
15
PDF
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
2023
·
Jérémy Béguin
, Eve Laloy
, et al.
·
Molecular Therapy — Oncolytics
·
12
PDF
Constitutive Expression of the Adenovirus E3-14.7K Protein Does Not Prolong Adenovirus Vector DNA Persistence but Protects Mice Against Lipopolysaccharide-Induced Acute Hepatitis
2002
·
Murielle Gantzer
, Estelle Spitz
, et al.
·
Human Gene Therapy
·
11
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
2020
·
Jérémy Béguin
, Virginie Nourtier
, et al.
·
BMC Veterinary Research
·
9
PDF
Abstract 1446: Characterization, evaluation and safety studies of the oncolytic Vaccinia virus TG6002 for canine cancer therapy
2019
·
Jérémy Béguin
, Johann Foloppe
, et al.
·
Cancer Research
·
2
Abstract 2497: Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
2015
·
Karola Rittner
, Christelle Remy-Ziller
, et al.
·
Cancer Research
·
1
Supplementary Figure Legend from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Table 1 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Figure 1 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Figure 2 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Figure 3 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Data from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Figure 2 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Supplementary Figure 1 from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Data from Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2023
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
Data from Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
2023
·
Laetitia Fend
, Takahiro Yamazaki
, et al.
Supplementary Figure Legends from Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
2023
·
Laetitia Fend
, Takahiro Yamazaki
, et al.
Show more works
View as search
Works count:
43
Citation count:
1,189
H-index:
11
I10-index:
11
Year
Topic
Type